Baseline characteristics of AYLHIV by age group
| Characteristics | Total | Young adolescents (10–14 years) | Older adolescents (15–19 years) | Young adults (20–24 years) | χ2 p value |
| AYLHIV (N, %) | 13 527 (100%) | 1170 (8.70) | 3206 (23.70) | 9151 (67.60) | |
| Female, n (%) | 11 380 (84.10) | 656 (56.10) | 2658 (82.90) | 8066 (88.10) | |
| Age at enrolment (median, IQR) | 21 (19–23) | 12 (10–13) | 18 (17–19) | 22 (21-23) | |
| Female | 21 (19–23) | 10 (12–13) | 18 (17–19) | 22 (21–23) | |
| Male | 20 (15–22) | 10 (12–13) | 17 (16–18) | 22 (21–24) | |
| Marital status, n (%) | 0.00 | ||||
| Single | 1481 (33.40) | 169 (82.40) | 492 (46.60) | 820 (25.90) | |
| Married | 2365 (53.40) | 18 (8.80) | 453 (42.90) | 1894 (59.80) | |
| Others | 581 (13.10) | 18 (8.80) | 111 (10.50) | 453 (14.30) | |
| Missing | 9100 | 965 | 2150 | 5985 | |
| Pregnancy status, n (% of females) | 0.06 | ||||
| Pregnant | 121 (1.00) | 1 (0.20) | 32 (1.20) | 88 (1.10) | |
| Non-pregnant | 8971 (99.00) | 130 (99.80) | 2031 (98.80) | 6810 (98.90) | |
| Missing | 2288 | 525 | 595 | 1168 | |
| Education, n (%) | 0.00 | ||||
| None/informal | 1072 (34.60) | 45 (31.00) | 257 (33.70) | 770 (35.10) | |
| Primary | 610 (19.70) | 60 (41.40) | 171 (22.40) | 379 (17.30) | |
| Secondary and higher | 1418 (45.70) | 40 (27.60) | 334 (43.80) | 1044 (47.60) | |
| Missing | 10 427 | 1025 | 2444 | 6958 | |
| Level of care, n (%) | |||||
| Secondary | 12 658 (93.60) | 1041 (89.00) | 2940 (91.70) | 8677 (94.80) | 0.00 |
| Tertiary | 869 (6.40) | 129 (11.00) | 266 (8.30) | 474 (5.20) | |
| Year of ART initiation, n (%) | 0.00 | ||||
| 2015 | 4509 (33.30) | 343 (29.30) | 1037 (32.30) | 3129 (34.20) | |
| 2016 | 4997 (36.90) | 430 (36.80) | 1233 (38.50) | 3334 (36.40) | |
| 2017 | 4021 (29.70) | 397 (33.90) | 936 (29.20) | 2688 (29.40) | |
| Baseline CD4 cells/mL (median, IQR) | 345 (198–516) | 399 (185–634) | 348 (201–515) | 337 (198–508) | |
| Baseline immunodeficiency, n (%) | 0.00 | ||||
| None (CD4 ≥500 cells/mL) | 1432 (26.90) | 157 (34.90) | 346 (27.00) | 929 (25.80 | |
| Mild (CD4 ≥350–499 cells/mL) | 1190 (22.30) | 100 (22.30) | 287 (22.40) | 803 (22.30) | |
| Advanced (CD4 ≥200–349 cells/mL) | 1364 (25.60) | 76 (16.90) | 332 (25.90) | 956 (26.60) | |
| Severe (CD4 <200 cells/mL) | 1342 (25.20) | 116 (25.80) | 316 (24.70) | 910 (25.30) | |
| Missing | 8199 | 721 | 1925 | 5553 | |
| TB status at baseline, n (%) | 0.27 | ||||
| No signs or symptoms of TB | 7442 (92.70) | 589 (92.90) | 1794 (92.60) | 5059 (92.70) | |
| Presumptive or confirmed TB | 443 (5.50) | 32 (5.00) | 100 (5.20) | 311 (5.70) | |
| On IPT | 143 (1.80) | 13 (2.10) | 44 (2.30) | 86 (1.60) | |
| Missing | 5499 | 536 | 1268 | 3695 | |
| WHO stage, n (%) | 0.00 | ||||
| 1 | 6475 (77.70) | 493 (74.00) | 1584 (79.30) | 4398 (77.60) | |
| 2 | 1272 (15.30) | 105 (15.80) | 274 (13.70) | 893 (15.80) | |
| 3 | 517 (6.20) | 61 (9.20) | 119 (6.00) | 337 (5.90) | |
| 4 | 67 (0.80) | 7 (1.00) | 21 (1.00) | 39 (0.70) | |
| Missing | 5196 | 504 | 1208 | 3484 | |
| Baseline ART regimen, n (%) | 0.00 | ||||
| ABC or AZT/3TC/EFV or NVP | 2048 (15.10) | 740 (63.20) | 466 (14.50) | 842 (9.20) | |
| ABC or AZT/3TC/ATVr or LPVr | 38 (0.30) | 9 (0.80) | 16 (0.50) | 13 (0.10) | |
| TDF/3TC/EFV or NVP | 11 349 (83.90) | 409 (35.00) | 2691(83.90) | 8249 (90.10) | |
| TDF/3TC/ATVr or LPVr | 32 (0.20) | 2 (0.20) | 18 (0.60) | 12 (0.10) | |
| Others | 60 (0.40) | 10 (0.90) | 15 (0.50) | 35 (0.40) |
ART, antiretroviral therapy; AYLHIV, adolescents and youths living with HIV; TB, tuberculosis.